Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC7401 in Primary Hypercholesterolemia or Mixed Hyperlipidemia
NCT07441317Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Small Molecules
01
Overview
A Phase 3 trial of rbd7022 in hypercholesterolemia, mixed hyperlipidemia, sponsored by Qilu Pharmaceutical. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
rbd7022
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT07441317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441317.